PMID- 28273279
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20220310
IS  - 1809-452X (Electronic)
IS  - 1516-4446 (Print)
IS  - 1516-4446 (Linking)
VI  - 39
IP  - 3
DP  - 2017 Jul-Sep
TI  - TBARS and BDNF levels in newborns exposed to crack/cocaine during pregnancy: a 
      comparative study.
PG  - 263-266
LID - 10.1590/1516-4446-2016-2035 [doi]
AB  - OBJECTIVES: To compare levels of a marker of lipid peroxidation (thiobarbituric 
      acid reactive substances, TBARS) and brain-derived neurotrophic factor (BDNF) in 
      umbilical cord blood (UCB) between newborns exposed to crack/cocaine in utero 
      (exposed newborns [EN], n=57) and non-exposed newborns (NEN, n=99), as well as in 
      maternal peripheral blood at delivery. METHODS: This was a cross-sectional study. 
      Potential confounders, including perinatal parameters, psychopathology, and use 
      of other substances, were assessed. RESULTS: After adjusting for potential 
      confounders, adjusted mean BDNF was significantly higher in EN (3.86 ng/mL, 95% 
      confidence interval [95%CI] 2.29-5.43) than in NEN (0.85 ng/mL, 95%CI 0.47-1.23; 
      p < 0.001; Cohen effect size: 1.12), and significantly lower in crack/cocaine 
      mothers than in control mothers (4.03 ng/mL, 95%CI 2.87-5.18 vs. 6.67 ng/mL, 
      95%CI 5.60-7.74; p = 0.006). The adjusted mean TBARS level was significantly 
      lower in EN (63.97 microM MDA, 95%CI 39.43-88.50) than NEN (177.04 microM MDA, 95%CI 
      140.93-213.14; p < 0.001; effect size = 0.84), with no difference between mother 
      groups (p = 0.86). CONCLUSIONS: The changes in TBARS levels observed in EN 
      suggest that fetuses exposed to cocaine mobilize endogenous antioxidant routes 
      since very early stages of development. The increase in BDNF levels in EN might 
      indicate changes in fetal development, whereas the changes in BDNF levels in 
      mothers provide evidence of the complex metabolic processes involved in drug use 
      during pregnancy.
FAU - Mardini, Victor
AU  - Mardini V
AD  - Servico de Psiquiatria da Infancia e Adolescencia (SPIA), Hospital de Clinicas de 
      Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
AD  - Programa de Pos-Graduacao em Medicina: Psiquiatria, Universidade Federal do Rio 
      Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
FAU - Rohde, Luis A
AU  - Rohde LA
AD  - Servico de Psiquiatria da Infancia e Adolescencia (SPIA), Hospital de Clinicas de 
      Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
AD  - Programa de Pos-Graduacao em Medicina: Psiquiatria, Universidade Federal do Rio 
      Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
AD  - Instituto Nacional de Psiquiatria do Desenvolvimento (INPD), Sao Paulo, SP, 
      Brazil.
AD  - Departamento de Psiquiatria, UFRGS, Porto Alegre, RS, Brazil.
FAU - Cereser, Keila M
AU  - Cereser KM
AD  - Programa de Pos-Graduacao em Medicina: Psiquiatria, Universidade Federal do Rio 
      Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
AD  - Laboratorio de Psiquiatria Molecular, Instituto Nacional de Ciencia e Tecnologia 
      Translacional em Medicina (INCT-TM), HCPA, UFRGS, Porto Alegre, RS, Brazil.
FAU - Gubert, Carolina M
AU  - Gubert CM
AD  - Laboratorio de Psiquiatria Molecular, Instituto Nacional de Ciencia e Tecnologia 
      Translacional em Medicina (INCT-TM), HCPA, UFRGS, Porto Alegre, RS, Brazil.
FAU - Silva, Emily G da
AU  - Silva EGD
AD  - Laboratorio de Psiquiatria Molecular, Instituto Nacional de Ciencia e Tecnologia 
      Translacional em Medicina (INCT-TM), HCPA, UFRGS, Porto Alegre, RS, Brazil.
FAU - Xavier, Fernando
AU  - Xavier F
AD  - Faculdade de Ciencias Biomedicas, Centro Universitario Metodista IPA, Porto 
      Alegre, RS, Brazil.
FAU - Parcianello, Rodrigo
AU  - Parcianello R
AD  - Programa de Pos-Graduacao em Medicina: Psiquiatria, Universidade Federal do Rio 
      Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
FAU - Rohsig, Liane M
AU  - Rohsig LM
AD  - Unidade de Criobiologia, Banco de Cordao Umbilical e Placentario, HCPA, Porto 
      Alegre, RS, Brazil.
FAU - Pechansky, Flavio
AU  - Pechansky F
AD  - Programa de Pos-Graduacao em Medicina: Psiquiatria, Universidade Federal do Rio 
      Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
AD  - Departamento de Psiquiatria, UFRGS, Porto Alegre, RS, Brazil.
AD  - Centro de Pesquisa em Alcool e Drogas, HCPA, UFRGS, Porto Alegre, RS, Brazil.
FAU - Szobot, Claudia M
AU  - Szobot CM
AD  - Servico de Psiquiatria da Infancia e Adolescencia (SPIA), Hospital de Clinicas de 
      Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
AD  - Programa de Pos-Graduacao em Medicina: Psiquiatria, Universidade Federal do Rio 
      Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
AD  - Centro de Pesquisa em Alcool e Drogas, HCPA, UFRGS, Porto Alegre, RS, Brazil.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170302
PL  - Brazil
TA  - Braz J Psychiatry
JT  - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
JID - 100895975
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Crack Cocaine)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cocaine-Related Disorders/blood
MH  - Crack Cocaine/*pharmacology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Fetal Blood/*chemistry
MH  - Humans
MH  - Infant, Newborn
MH  - Middle Aged
MH  - Oxidation-Reduction/drug effects
MH  - Postpartum Period/blood
MH  - Pregnancy
MH  - Thiobarbituric Acid Reactive Substances/*analysis
MH  - Young Adult
PMC - PMC7111386
COIS- LAR has received honoraria, has been on the speakers' bureau/advisory board, 
      and/or has acted as a consultant for Eli-Lilly, Janssen-Cilag, Novartis, and 
      Shire in the last 3 years; receives authorship royalties from Oxford Press and 
      ArtMed; and has received travel awards from Shire for taking part in 2014 APA and 
      2015 WFADHD meetings. The ADHD and Juvenile Bipolar Disorder Outpatient Programs 
      chaired by him received unrestricted educational and research support from the 
      following pharmaceutical companies in the last 3 years: Eli-Lilly, Janssen-Cilag, 
      Novartis, and Shire. CMS has been on the speakers' bureau for Novartis. The other 
      authors report no conflicts of interest.
EDAT- 2017/03/09 06:00
MHDA- 2017/11/07 06:00
PMCR- 2017/03/02
CRDT- 2017/03/09 06:00
PHST- 2016/06/29 00:00 [received]
PHST- 2016/09/28 00:00 [accepted]
PHST- 2017/03/09 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
PHST- 2017/03/09 06:00 [entrez]
PHST- 2017/03/02 00:00 [pmc-release]
AID - S1516-44462017005004102 [pii]
AID - 10.1590/1516-4446-2016-2035 [doi]
PST - ppublish
SO  - Braz J Psychiatry. 2017 Jul-Sep;39(3):263-266. doi: 10.1590/1516-4446-2016-2035. 
      Epub 2017 Mar 2.